Xenotransplantation of cells using biodegradable microcapsules.

BACKGROUND The use of immunoisolation to protect transplanted cells from the immune system of the host has broad application to the treatment of major diseases such as diabetes and a wide range of other disorders resulting from functional defects of native cell systems. In most cases, limitations in functional cell longevity will necessitate periodic replenishment of the cells. We describe a hydrogel-based microcapsule that breaks down at a rate that can be adjusted to correspond to the functional longevity of the encapsulated cells. These injectable capsules can be engineered to degrade over several weeks to months for short-term drug delivery, or to remain intact and immunoprotective for more extended periods. When the supply of cells needs to be replenished, no surgery will be required to localize and remove the old capsules. METHODS Porcine and bovine islets were immobilized in "composite" microcapsules fabricated from alginate and low-relative molecular mass (Mr) poly (L-lysine[PLL]) (Mr exclusion <120 Kd) and implanted into the peritoneum of normal and streptozotocin-induced diabetic rats. In addition to demonstrating long-term islet viability and function, a series of in vitro studies were carried out to determine the permeability and biodegradability of the microcapsules used in the present system. RESULTS Xenogeneic islets implanted in nonimmunosuppressed rats remained in excellent condition indefinitely (>40 weeks)(viability was comparable to that of preimplant control specimens). In contrast, no islets survived in uncoated alginate spheres after 2 weeks postimplantation. By changing the concentration of the alginate, it was possible to vary the rate of capsule breakdown in rats from mechanically unstable (outer matrix <0.5-0.75% alginate) to stable for >1 year (> or =1.5% alginate). In addition to in vivo breakdown studies, the biodegradability of the capsular components was verified in vitro using a mixture of tritosomes (enzymes isolated from animal cells). CONCLUSIONS We have designed a microcapsule system with controllable biodegradability which allows breakdown and absorption of implants when the cells die or become functionally inactive. These results may have application to other alginate-PLL encapsulation systems. The ability to cross species lines using these biodegradable microcapsules has the potential to expand dramatically the number of patients and the scope of diseases that can be successfully treated with cellular therapy.

[1]  F. Lim,et al.  Microencapsulated islets as bioartificial endocrine pancreas. , 1980, Science.

[2]  S. Barnett,et al.  The effects of calcium alginate on wound healing. , 1987, Annals of the Royal College of Surgeons of England.

[3]  G. Warnock,et al.  Critical Mass of Purified Islets That Induce Normoglycemia After Implantation Into Dogs , 1988, Diabetes.

[4]  G. Karakiulakis,et al.  Comparative evaluation of mitogenicity and basement-membrane-degrading activity of Pseudomonas aeruginosa slime glycolipoprotein and alginate , 1989, Journal of clinical microbiology.

[5]  B A Solomon,et al.  Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Colton,et al.  Bioengineering in development of the hybrid artificial pancreas. , 1991, Journal of biomechanical engineering.

[7]  R. Lanza,et al.  Perspectives in diabetes. Islet transplantation with immunoisolation. , 1992, Diabetes.

[8]  P. Vanstraelen Comparison of calcium sodium alginate (KALTOSTAT) and porcine xenograft (E-Z DERM) in the healing of split-thickness skin graft donor sites. , 1992, Burns : journal of the International Society for Burn Injuries.

[9]  Robert Lanza,et al.  Islet Transplantation With Immunoisolation , 1992, Diabetes.

[10]  R. Browne,et al.  Tissue response to a haemostatic alginate wound dressing in tooth extraction sockets. , 1993, The British journal of oral & maxillofacial surgery.

[11]  G. Skjåk-Bræk,et al.  Long-term reversal of diabetes by the injection of immunoprotected islets. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Lodge,et al.  Treatment of severe diabetes mellitus for more than one year using a vascularized hybrid artificial pancreas. , 1993, Transplantation.

[13]  F. Leblond,et al.  PROTECTION OF ISLETS OF LANGERHANS FROM ANTIBODIES BY MICROENCAPSULATION WITH ALGINATE‐POLY‐L‐LYSINE MEMBRANES1 , 1993, Transplantation.

[14]  I. Miller,et al.  First pregnancies and livebirths from transfer of sodium alginate encapsulated embryos in a rodent model. , 1993, Fertility and sterility.

[15]  R. Lanza,et al.  Biohybrid artificial pancreas. Long-term function of discordant islet xenografts in streptozotocin diabetic rats. , 1993, Transplantation.

[16]  A. Mikos,et al.  Mini‐review: Islet transplantation to create a bioartificial pancreas , 1994, Biotechnology and bioengineering.

[17]  C. Gartung,et al.  The subcellular localization of a bile acid glucosyltransferase in rat liver. , 1994, Journal of hepatology.

[18]  Ruth Duncan,et al.  Radioiodination of Alginate via Covalently-Bound Tyrosinamide Allows Monitoring of its Fate In Vivo , 1995 .

[19]  C. Colton,et al.  Implantable biohybrid artificial organs. , 1995, Cell transplantation.

[20]  D. Ecker,et al.  Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. , 1995, Transplantation.

[21]  P. Brunetti,et al.  Coherent microcapsules for pancreatic islet transplantation: a new approach for bioartificial pancreas. , 1996, Transplantation proceedings.

[22]  P. Bruheim,et al.  Alginate polycation microcapsules. II. Some functional properties. , 1996, Biomaterials.

[23]  R. Lanza,et al.  Encapsulated cell technology , 1996, Nature Biotechnology.

[24]  P. Bruheim,et al.  Alginate polycation microcapsules. I. Interaction between alginate and polycation. , 1996, Biomaterials.

[25]  R. Lanza,et al.  Immunoisolation: at a turning point. , 1997, Immunology today.

[26]  G. Weir,et al.  Scientific and Political Impediments to Successful Islet Transplantation , 1997, Diabetes.

[27]  T. Stockley,et al.  Non‐Autologous Transplantation with Immuno‐isolation in Large Animals—A Review , 1997, Annals of the New York Academy of Sciences.

[28]  A. Anilkumar,et al.  An encapsulation system for the immunoisolation of pancreatic islets , 1997, Nature Biotechnology.

[29]  P. Chang,et al.  Delivery of recombinant gene product to canines with nonautologous microencapsulated cells. , 1998, Human gene therapy.

[30]  T. Chang,et al.  Therapeutic uses of microencapsulated genetically engineered cells. , 1998, Molecular medicine today.

[31]  E. Chaikof,et al.  Long-Term Survival of Poly-L-Lysine-Alginate Microencapsulated Islet Xenografts in Spontaneously Diabetic NOD Mice , 1999 .